Clobex/Vectical "effective" in managing psoriasis

16 March 2009

French dermatology-focused drugmaker Galderma Laboratories says interim findings from a study of sequential treatment of plaque  psoriasis using Clobex (clobetasol propionate) spray 0.05% followed by  treatment with Vectical (calcitriol) ointment 3mcg/g showed positive  results.

While both products are indicated for the treatment of plaque  psoriasis, this study was conducted to confirm the safety and efficacy  of these products when used in a sequential regimen. In this study,  Clobex spray was used in the initial phase of the study to treat  moderate-to-severe plaque psoriasis. For subjects sufficiently clear  at the end of four weeks, Vectical ointment was applied twice-daily for  eight weeks. Success was evaluated at week-12 based on Overall Disease  Severity scores.

The interim results indicate that sequential treatment of plaque  psoriasis with Clobex spray followed by Vectical ointment is effective  in managing plaque psoriasis over a 12-week period. Additionally, the  interim results demonstrate that this sequential treatment regimen was  well tolerated, with the most commonly reported side effects including  mild-to-moderate itching, stinging and burning and telangectasias (small  dilated blood vessels near the surface of the skin).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight